Cidara Therapeutics skyrockets 1,165% after positive CD388 data and Merck's acquisition bid. Read why CDTX stock is a Hold.

It was huge. Its light brown shell stood taller than the tip of my shoe. Its yellowish-green body stretched about an inch ...

A House Republican has filed a bill that says health-care providers could not “discriminate” against patients based on ...

CX-5461 is the first G-quadruplex (G4) stabilizer in development. It has shown promising activity in early-phase trials for ...

Calling it the “Health Care Medical Freedom Act,” a House Republican on Monday filed a bill that says health-care providers ...

Learn more about whether Travere Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Twist Bioscience Corporation or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The new bill, called the "Health Care Medical Freedom Act," would, in part, prohibit Florida providers from refusing to see ...

The past year saw a number of significant actions at the state and federal levels that could transform how health care is ...

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

Day One Biopharmaceuticals’ fair value estimate remains steady at $22.25 per share, even as the Mersana acquisition adds a second antibody drug conjugate and broadens its oncology platform. While the ...